Dermata Therapeutics, Inc. (DRMA) intrinsic value & 10-year financials
Dermata Therapeutics, Inc. (DRMA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.86
- Market cap
- $796.5K
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 211.3%
- Free cash flow (FY2025)
- —
DRMA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$7.6M | -$8.16 | — | — | -194.2% |
| FY2024 | — | -$12.3M | -$8.03 | — | — | -316.1% |
| FY2023 | — | -$7.8M | -$5.00 | — | — | -130.0% |
| FY2022 | — | -$9.6M | — | — | — | 1398.6% |
| FY2021 | — | -$7.9M | — | — | — | 408.8% |
| FY2020 | — | -$3.2M | — | — | — | 100.7% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Dermata Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Dermata Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -2.7% ROIC.
Dermata Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Dermata Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.